Suppr超能文献

通用嵌合抗原受体用于 T 细胞反应的多重和逻辑控制。

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses.

机构信息

Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA; Biological Design Center, Boston University, Boston, MA 02215, USA.

Synthetic Biology Center, MIT, Cambridge, MA 02139, USA; Institute for Medical Engineering and Science, MIT, Cambridge, MA 02139, USA; Department of Biological Engineering, MIT, Cambridge, MA 02139, USA; Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, 415 Main Street, Cambridge, MA 02142, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, 3 Blackfan Circle, Boston, MA 02115, USA.

出版信息

Cell. 2018 May 31;173(6):1426-1438.e11. doi: 10.1016/j.cell.2018.03.038. Epub 2018 Apr 26.

Abstract

T cells expressing chimeric antigen receptors (CARs) are promising cancer therapeutic agents, with the prospect of becoming the ultimate smart cancer therapeutics. To expand the capability of CAR T cells, here, we present a split, universal, and programmable (SUPRA) CAR system that simultaneously encompasses multiple critical "upgrades," such as the ability to switch targets without re-engineering the T cells, finely tune T cell activation strength, and sense and logically respond to multiple antigens. These features are useful to combat relapse, mitigate over-activation, and enhance specificity. We test our SUPRA system against two different tumor models to demonstrate its broad utility and humanize its components to minimize potential immunogenicity concerns. Furthermore, we extend the orthogonal SUPRA CAR system to regulate different T cell subsets independently, demonstrating a dually inducible CAR system. Together, these SUPRA CARs illustrate that multiple advanced logic and control features can be implemented into a single, integrated system.

摘要

表达嵌合抗原受体 (CAR) 的 T 细胞是很有前途的癌症治疗剂,有望成为终极智能癌症治疗剂。为了扩展 CAR T 细胞的能力,在这里,我们提出了一种分裂的、通用的和可编程的 (SUPRA) CAR 系统,它同时包含了多个关键的“升级”,例如无需重新设计 T 细胞即可切换靶标、精细调节 T 细胞激活强度以及感知和逻辑响应多种抗原的能力。这些功能有助于对抗复发、减轻过度激活并提高特异性。我们使用两种不同的肿瘤模型来测试我们的 SUPRA 系统,以证明其广泛的适用性,并对其组件进行人源化处理,以最大程度地减少潜在的免疫原性问题。此外,我们将正交 SUPRA CAR 系统扩展到独立调节不同的 T 细胞亚群,展示了一种双重诱导型 CAR 系统。总之,这些 SUPRA CAR 表明,可以将多个高级逻辑和控制功能集成到单个集成系统中。

相似文献

引用本文的文献

1
Optimised modular anti-FLAG CAR T cells for solid tumor therapy.用于实体瘤治疗的优化模块化抗FLAG嵌合抗原受体T细胞
Clin Transl Immunology. 2025 Aug 21;14(8):e70046. doi: 10.1002/cti2.70046. eCollection 2025.
4
Precision sniper for solid tumors: CAR-NK cell therapy.实体瘤的精准狙击:CAR-NK细胞疗法。
Cancer Immunol Immunother. 2025 Jul 24;74(9):275. doi: 10.1007/s00262-025-04106-z.

本文引用的文献

3
Therapeutic T cell engineering.治疗性T细胞工程
Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395.
5
Toxicity and management in CAR T-cell therapy.嵌合抗原受体 T 细胞疗法的毒性与管理。
Mol Ther Oncolytics. 2016 Apr 20;3:16011. doi: 10.1038/mto.2016.11. eCollection 2016.
8
Toxicities of chimeric antigen receptor T cells: recognition and management.嵌合抗原受体T细胞的毒性:识别与管理
Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验